Matches in Wikidata for { <http://www.wikidata.org/entity/Q104138816> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q104138816 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 9ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104138816 description "article scientifique publié en 2020" @default.
- Q104138816 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104138816 description "scientific article published on 09 December 2020" @default.
- Q104138816 description "wetenschappelijk artikel" @default.
- Q104138816 description "наукова стаття, опублікована 9 грудня 2020" @default.
- Q104138816 description "գիտական հոդված հրատարակված 2020 թվականի դեկտեմբերի 9-ին" @default.
- Q104138816 name "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 name "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 name "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 type Item @default.
- Q104138816 label "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 label "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 label "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 prefLabel "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 prefLabel "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 prefLabel "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 P1433 Q104138816-278F9823-2B1A-4964-AEDF-485981BA6409 @default.
- Q104138816 P1476 Q104138816-58389877-1ED5-4E0C-8EC1-D81BF6727874 @default.
- Q104138816 P2093 Q104138816-1300BF83-489A-4560-922A-61106842ACF3 @default.
- Q104138816 P2093 Q104138816-47FD5733-6805-48FD-B380-FD84EC40BC5F @default.
- Q104138816 P2093 Q104138816-67D750AF-97D6-40C5-8B6D-6A3CE9B5C70A @default.
- Q104138816 P2093 Q104138816-6E77631E-B078-4E90-8556-B9CD242423FB @default.
- Q104138816 P2093 Q104138816-7F70E4AD-EE3B-4259-9D31-E1A8DA05C5EA @default.
- Q104138816 P2093 Q104138816-A7ABCCDF-4140-4812-BAAB-567E0AE9F8BA @default.
- Q104138816 P2093 Q104138816-EFAF5809-9C53-4F41-8B4B-8C487014B8D7 @default.
- Q104138816 P2093 Q104138816-FEB49BC8-4B05-4BB9-9EAC-91DE292C3592 @default.
- Q104138816 P31 Q104138816-3D13454B-4061-4093-80CA-9F172E587B33 @default.
- Q104138816 P31 Q104138816-5F310197-C0A4-4A19-97F1-91C70AABB0D0 @default.
- Q104138816 P356 Q104138816-836287B7-33B0-4780-A9CF-95504878A92E @default.
- Q104138816 P577 Q104138816-D0E53471-AD98-4767-966B-453CB27A2E4D @default.
- Q104138816 P698 Q104138816-FA76BC45-6917-4423-B443-22B41C2989D6 @default.
- Q104138816 P921 Q104138816-E7B4A975-8752-489D-BECA-AC512A5E20DA @default.
- Q104138816 P356 S00467-020-04874-Z @default.
- Q104138816 P698 33296010 @default.
- Q104138816 P1433 Q15749796 @default.
- Q104138816 P1476 "Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab" @default.
- Q104138816 P2093 "Alvaro Madrid Aris" @default.
- Q104138816 P2093 "Brigitte Adams" @default.
- Q104138816 P2093 "Kazuki Tanaka" @default.
- Q104138816 P2093 "Larry A Greenbaum" @default.
- Q104138816 P2093 "Marc Vallee" @default.
- Q104138816 P2093 "Masayo Ogawa" @default.
- Q104138816 P2093 "Naoya Fujita" @default.
- Q104138816 P2093 "Stephan Ortiz" @default.
- Q104138816 P31 Q13442814 @default.
- Q104138816 P31 Q1348305 @default.
- Q104138816 P356 "10.1007/S00467-020-04874-Z" @default.
- Q104138816 P577 "2020-12-09T00:00:00Z" @default.
- Q104138816 P698 "33296010" @default.
- Q104138816 P921 Q17165460 @default.